Print
Moa video: How CYTOPOINT® works
CYTOPOINT is the first and only caninized monoclonal antibody (mAb) treatment for dogs that specifically targets and neutralizes canine IL-31, with minimal impact on normal immune functions1,2
The power of the injectable: healthy patients, healthy clinics
Veterinary injectable medications eliminate potential barriers to compliance and provide quick relief to patients and peace of mind to clients. See how injectables can benefit your clinic at poweroftheinjectable.com
CYTOPLAN: A TREATMENT PLAN FOR YOUR PATIENTS
Guide your clients through CYTOPOINT treatment and ensure compliance with a CYTOPLAN
Diagnostic approach to the itchy dog
Together, we continue to change the way we approach canine pruritus
CYTOPOINT package insert
Pet owner handouts and materials
Reminders
Encourage pet owners to sign up for email and text reminders of their dog’s next CYTOPOINT injection to ensure compliance
Pet owner brochure
This take-home resource will help your clients get the most from their dog’s CYTOPOINT treatment
Dosing chart
This handy reminder of the proper dosing of CYTOPOINT can be placed in a convenient location
Itch Tracker
This printout helps clients track their dog’s itch improvement and record changes in their quality of life
STUDY DESIGN
This was a multi-centered prospective open observational Phase IV study with an objective of understanding the efficacy of 3 monthly dosages of CYTOPOINT® in dogs with atopic dermatitis (AD) (n=110). Dogs were evaluated weekly for pruritus and monthly for clinical signs of AD to understand the benefit of consecutive monthly dosing and the duration of treatment effect. Single doses were administered on study Day 0, then further on Day 30, with Day 60 dependent on clinical response. Treatment success was defined as achieving a 20 mm reduction in PVAS from baseline. Inclusion and exclusion criteria were intended to ensure enrollment of dogs with AD but without other concurrent disease or pharmaceutical treatments that could confound the study. Dogs had a documented history of non-seasonal AD or seasonal AD where prior history supported disease preferences for at least 4 months following initiation treatment.
CONTACT US
United States 
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2022 Zoetis Services LLC. All rights reserved.
